SCHEDULE 13G/A: Alyeska Investment Group Discloses 2.5% Stake in Kiora Pharmaceuticals

Alyeska Investment Group, L.P. and its affiliates reported a beneficial ownership of 2.5% of Kiora Pharmaceuticals, Inc.'s common stock as of December 31, 2024, through warrants.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh collectively reported beneficial ownership of 75,628 shares of Kiora Pharmaceuticals, Inc. common stock.
• This ownership represents 2.5% of the Issuer's outstanding common stock.
• The reported shares are in the form of warrants to purchase common stock.
• The percentage calculation is based on 3,000,788 outstanding shares of common stock as reported in Kiora Pharmaceuticals' Form 10-Q filed on November 8, 2024.
• The filing is an Amendment No. 1 to Schedule 13G, indicating a change from a previous filing.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: Neutral. This is a factual disclosure of beneficial ownership and does not contain information that would significantly alter sentiment about the company's operations or prospects.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership, indicating a notable, albeit non-controlling, stake by Alyeska Investment Group.

Key Dates

Keywords

Kiora Pharmaceuticals, Alyeska Investment Group, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, SEC Filing